P008 Hydroxychloroquine-related adverse events, attrition and reasons for cessation over 5 years at a district general hospital: estimating future ophthalmology screening service use

Abstract Background/Aims Hydroxychloroquine (HCQ) is used widely in the management of rheumatic diseases and considered to be generally well tolerated. HCQ ocular toxicity a dose- time-related reaction. The Royal College Ophthalmologists (RCOphth) noted low rate drug discontinuation as result baseline testing (< 4%) that prevalence data for was based on treatment duration >5 years. RCOphth updated their screening guideline 2020. A major change removal requirement screening, with commenced at 5 years unless risk factors are present. Though number patients starting UK prescribing could estimated, proportion remaining stated unknown. We reviewed departmental prescribing, adverse event attrition over from Bolton NHS Foundation Trust, district general hospital which serves population nearly 300,000. Methods Patients were identified newly commencing if they had shared care agreement calendar year 2016. Adverse events, rates reasons cessation obtained through review records Results In 2016 year, 100 HCQ. mean age 58, 70% female. most common indication rheumatoid arthritis (75%). At 1 30% stopped taking 57% reason gastrointestinal symptoms (30%), remained (19%). Eye documented 7% 5% On records, none these thought attributable HCQ, though it not recommenced. There no patient deaths directly use. Conclusion significant (57%) after highest within 12 months, then almost doubled by Centres wishing estimate workload related retinopathy can capture and/or catchment numbers Ophthalmology activity this years' hence. This may help fund staff adequately successfully carry out safety activity. Disclosure D. Barahman: None. C. Saleh: A. Paul: